The first experience of using a ready-to-use liquid form of a hypercaloric semi-elemental product for enteral nutrition in children with cystic fibrosis

In recent years, great progress has been associated with the use of targeted therapy (since 2012 in world practice, since 2021 in the Russian Federation) in the treatment of cystic fibrosis. The use of pathogenetic therapy improves the nutritional status and functional state of the lungs. However, the problem of nutritional insufficiency in a number of patients with cystic fibrosis still persists. Objective. To evaluate the dynamics of anthropometric indicators and body composition using bioimpedance analysis in children with cystic fibrosis against the background of dietary correction using a semi-elemental hypercaloric product. Material and methods. The analysis of the results of the examination of patients meeting the inclusion criteria was carried out retrospectively according to the primary medical documentation. The program included only the primary medical documentation of patients, containing all the data necessary for the assessment of primary and secondary points. Design: single-center, retrospective in one group. Results. The results of observation of 20 patients with a BMI of less than 50 percentile showed that the use of Peptamen Junior 1.5 formula for 90 ± 7 days increased BMI by an average of 0.6 kg/m2 and the proportion of skeletal muscle mass in lean body weight (SMM, %) by 1.3%. Conclusion. A retrospective analysis of the use of a semi-elemental liquid enteral nutrition product Peptamen Junior 1.5 for the correction of nutritional deficiency in children with cystic fibrosis aged 5 to 10 years indicates its clinical effectiveness for this category of patients. Key words: cystic fibrosis, children, semi-elemental formula, enteral nutrition, intestinal syndrome, Peptamen Junior 1.5, malabsorption